Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S6JG
|
|||
| Former ID |
DAP000082
|
|||
| Drug Name |
Liothyronine
|
|||
| Synonyms |
liothyronine; 3,3',5-Triiodo-L-thyronine; 6893/2/3; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; triothyrone; Liothyroninum; Liotironina; 3,5,3'-Triiodo-L-thyronine; L-T3; T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; Lyothyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Rathyronine; Triothyrone; THYROID HORMONE; Liothyronine I 131; Liothyronine I 131 [USAN]; T3 liothyronine; Cytomel (TN); Euthroid-1; Euthroid-2; Euthroid-3; Liothyronine (INN); Liothyroninum[INN-Latin]; Liotironina [INN-Spanish]; T3 (Triiodothyronine); T3 (VAN); Tertroxin (TN); Thyrolar-1; Thyrolar-2; Thyrolar-3; Tri-Thyrotope; Triiodothyronine (T3); Triomet-131; Euthroid-05; Thyrolar-025; Thyrolar-05; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Thyronine, 3,3',5-triiodo-, L-(6CI); L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI); 3,3'5-Triiodo-L-thyronine; 3,5,3'-Tri-iodo-L-thyronine; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypothyroidism [ICD-11: 5A00; ICD-10: E03.8, E03.9; ICD-9: 244] | Approved | [1] | |
| Congestive heart failure [ICD-11: BD10; ICD-10: I50.0; ICD-9: 428] | Phase 3 | [2] | ||
| Therapeutic Class |
Hormone Replacement Agents
|
|||
| Company |
King Pharmaceuticals, Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H12I3NO4
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O
|
|||
| InChI |
1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1
|
|||
| InChIKey |
AUYYCJSJGJYCDS-LBPRGKRZSA-N
|
|||
| CAS Number |
CAS 15785-49-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5481, 830311, 832593, 854428, 4253003, 7890655, 7980832, 8002138, 8145172, 8153668, 10321236, 11364339, 11364976, 11366901, 11367538, 11369463, 11370100, 11372994, 11373139, 11373810, 11375700, 11377625, 11378271, 11457873, 11466881, 11468001, 11485903, 11486522, 11489800, 11491702, 11492141, 11495259, 11532858, 14710501, 14710502, 14936961, 14964754, 24900088, 26737095, 26737097, 26753840, 29224945, 46393605, 46506352, 46518913, 47217059, 47291379, 47440547, 47440548, 47885656
|
|||
| ChEBI ID |
CHEBI:18258
|
|||
| ADReCS Drug ID | BADD_D01296 ; BADD_D01297 | |||
| SuperDrug ATC ID |
H03AA02
|
|||
| SuperDrug CAS ID |
cas=000055061
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thyroid hormone receptor alpha (THRA) | Target Info | Antagonist | [3], [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Thyroid hormone signaling pathway | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Endochondral Ossification | |||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | ClinicalTrials.gov (NCT00790738) Liothyronine (T3) for Bipolar Depression. U.S. National Institutes of Health. | |||
| REF 3 | Evaluation of thyroid hormone action in a case of generalized resistance to thyroid hormone with chronic thyroiditis: discovery of a novel heterozy... Endocr J. 2007 Dec;54(5):727-32. | |||
| REF 4 | Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):249-59. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.